Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth. Check out why I ...

Hims & Hers Health shares fell 4.1% Wednesday morning. Despite the pullback, the stock remains up an impressive 116% over the ...

Cathie Wood is known for two things: making daring investment moves that go against the crowd and doing this with a focus on ...

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue ...

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...